Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.

Lin MT, Chou YP, Hu TH, Yu HC, Hsu YC, Tsai MC, Tseng PL, Chang KC, Yen YH, Chiu KW.

Arch Virol. 2014 Jan;159(1):29-37. doi: 10.1007/s00705-013-1786-4. Epub 2013 Jul 16.

PMID:
23857507
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.

Park H, Park JY, Kim SU, Kim do Y, Han KH, Chon CY, Ahn SH.

World J Gastroenterol. 2013;19(43):7671-9. doi: 10.3748/wjg.v19.i43.7671.

PMID:
24431895
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.

Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ.

Antimicrob Agents Chemother. 2013 Jul;57(7):3369-74. doi: 10.1128/AAC.00587-13. Epub 2013 May 6.

PMID:
23650172
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.

Kim YJ, Paik SW, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC.

J Gastroenterol Hepatol. 2012 Sep;27(9):1454-60. doi: 10.1111/j.1440-1746.2011.07050.x.

PMID:
22168753
[PubMed - indexed for MEDLINE]
5.

Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.

Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ.

J Hepatol. 2010 Sep;53(3):449-54. doi: 10.1016/j.jhep.2010.03.020. Epub 2010 May 25.

PMID:
20646776
[PubMed - indexed for MEDLINE]
6.

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F; Club Epatologi Ospedalieri (CLEO) Group.

Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012.

PMID:
18343270
[PubMed - indexed for MEDLINE]
7.

The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.

Kim MC, Jung SW, Shin JW, Park NH.

Dig Dis Sci. 2011 Apr;56(4):1215-21. doi: 10.1007/s10620-010-1537-2. Epub 2011 Jan 8.

PMID:
21221793
[PubMed - indexed for MEDLINE]
8.

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.

Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA; 018 Study Group.

Ann Intern Med. 2007 Dec 4;147(11):745-54. Epub 2007 Oct 1.

PMID:
17909201
[PubMed - indexed for MEDLINE]
9.

Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.

Lee JM, Park JY, Kim do Y, Nguyen T, Hong SP, Kim SO, Chon CY, Han KH, Ahn SH.

Antivir Ther. 2010;15(2):235-41. doi: 10.3851/IMP1510.

PMID:
20386079
[PubMed - indexed for MEDLINE]
10.

Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.

Liu CJ, Kao JH, Chen PJ, Chen TC, Lin FY, Lai MY, Chen DS.

J Viral Hepat. 2006 Jun;13(6):387-95.

PMID:
16842441
[PubMed - indexed for MEDLINE]
11.

Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.

Lim YS, Lee TH, Heo NY, Shim JH, Lee HC, Suh DJ.

Antivir Ther. 2012;17(1):53-60. doi: 10.3851/IMP1914.

PMID:
22267469
[PubMed - indexed for MEDLINE]
12.

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL.

Gastroenterology. 2004 Jan;126(1):91-101.

PMID:
14699491
[PubMed - indexed for MEDLINE]
13.

Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.

Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV.

J Med Virol. 2008 Jul;80(7):1160-70. doi: 10.1002/jmv.21206.

PMID:
18461609
[PubMed - indexed for MEDLINE]
14.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

PMID:
20659226
[PubMed - indexed for MEDLINE]
15.

Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.

Mihm U, Gärtner BC, Faust D, Hofmann WP, Sarrazin C, Zeuzem S, Herrmann E.

J Hepatol. 2005 Aug;43(2):217-24.

PMID:
15964093
[PubMed - indexed for MEDLINE]
16.

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.

Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY.

J Med Virol. 2010 Nov;82(11):1835-42. doi: 10.1002/jmv.21898.

PMID:
20872709
[PubMed - indexed for MEDLINE]
17.

Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.

Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A, Papatheodoridis G, Karamanolis D, Tzourmakliotis D.

Aliment Pharmacol Ther. 2008 Feb 1;27(3):266-73. Epub 2007 Nov 5. Erratum in: Aliment Pharmacol Ther. 2008 Mar 15;27(6):528-9.

PMID:
17988233
[PubMed - indexed for MEDLINE]
Free Article
18.

Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir.

Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ.

Antimicrob Agents Chemother. 2012 Jun;56(6):2941-7. doi: 10.1128/AAC.00338-12. Epub 2012 Mar 19.

PMID:
22430972
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy.

Yu HC, Lin KH, Hsu PI, Tsay FW, Wang HM, Tsai TJ, Lai KH.

Clin Ther. 2013 Sep;35(9):1386-99. doi: 10.1016/j.clinthera.2013.07.329.

PMID:
24054706
[PubMed - indexed for MEDLINE]
20.

[Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].

Xing J, Han T, Liu L, Li Y, Li J, Li Y, Xiao SX.

Zhonghua Gan Zang Bing Za Zhi. 2011 Nov;19(11):828-32. doi: 10.3760/cma.j.issn.1007-3418.2011.11.009. Chinese.

PMID:
22433304
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk